Prospective Evaluation of Lipid Management Following Acute Coronary Syndrome in Saudi Arabia

Overview

Journal Saudi Med J

Specialty General Medicine

Date 2023 Jun 21

PMID 37343983

Authors

Mohammed R Arafah

Michael U Youssef

Faisal M AlSamadi

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate LDL-C control in patients within 6 months after hospitalization for ACS in Saudi Arabia.

Methods: This multicenter, prospective, observational registry evaluates LDL-C control in patients within 6 months after hospitalization for ACS in Saudi Arabia between December 2017 and October 2019. The study aimed at recruiting 170 patients and data were collected retrospectively at baseline and prospectively at 2 subsequent visits.

Results: 201 patients were included at baseline, 193 completed the 3-month visit and 186 completed the 6-month visit. Post-ACS, virtually all patients were prescribed high-intensity statins and LDL-C levels decreased consistently. However, at LDL-C target assessment, 57.1% of patients still had LDL-C levels >55 mg/dL, while 62.6% of patients had achieved LDL-C level decrease >50%. The composite milestone of LDL-C decrease >50% and LDL-C levels <55 mg/dL was met by 20.6% of study patients. Importantly, 37% of patients did not have LDL-C reading post-ACS and the primary outcome was only valuable for 126 out of 201 patients (63%).

Conclusion: Levels and decrease of LDL-C from baseline achieved in this study are suboptimal, according to updated 2019 ESC/EAS guidelines. While statins were prescribed to all patients post-ACS, the recommended add-on treatments were largely overlooked. Gaps in dyslipidemia management linger, despite clear updated guidelines.

References

Soppert J, Lehrke M, Marx N, Jankowski J, Noels H . Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev. 2020; 159:4-33. DOI: 10.1016/j.addr.2020.07.019. View

Rea F, Corrao G, Merlino L, Mancia G . Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018; 39(40):3654-3661. DOI: 10.1093/eurheartj/ehy420. View

Banach M, Penson P, Vrablik M, Bunc M, Dyrbus K, Fedacko J . Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021; 166:105499. DOI: 10.1016/j.phrs.2021.105499. View

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2020; 44(Suppl 1):S15-S33. DOI: 10.2337/dc21-S002. View

Alhabib K, Hersi A, AlFaleh H, Kurdi M, Arafah M, Youssef M . The Saudi Project for Assessment of Coronary Events (SPACE) registry: design and results of a phase I pilot study. Can J Cardiol. 2009; 25(7):e255-8. PMC: 2723036. DOI: 10.1016/s0828-282x(09)70513-6. View

Athyros V, Stavropoulos K, Imprialos K, Doumas M . Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data. Int J Cardiol. 2020; 316:240-241. PMC: 7334918. DOI: 10.1016/j.ijcard.2020.06.059. View

Reiter-Brennan C, Osei A, Uddin S, Orimoloye O, Obisesan O, Mirbolouk M . ACC/AHA lipid guidelines: Personalized care to prevent cardiovascular disease. Cleve Clin J Med. 2020; 87(4):231-239. DOI: 10.3949/ccjm.87a.19078. View

De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Ryden L . Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019; 285:135-146. DOI: 10.1016/j.atherosclerosis.2019.03.014. View

Walli-Attaei M, Rosengren A, Rangarajan S, Breet Y, Abdul-Razak S, Al Sharief W . Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. Lancet. 2022; 400(10355):811-821. DOI: 10.1016/S0140-6736(22)01441-6. View

10.

Hagstrom E, Steg P, Szarek M, Bhatt D, Bittner V, Danchin N . Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022; 146(9):657-672. PMC: 9422774. DOI: 10.1161/CIRCULATIONAHA.121.057807. View

11.

Al Sifri S, Almahmeed W, Azar S, Okkeh O, Bramlage P, Junger C . Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One. 2014; 9(1):e84350. PMC: 3882235. DOI: 10.1371/journal.pone.0084350. View

12.

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41(1):111-188. DOI: 10.1093/eurheartj/ehz455. View

13.

Kannel W, CASTELLI W, Gordon T . Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979; 90(1):85-91. DOI: 10.7326/0003-4819-90-1-85. View

14.

Keys A, Menotti A, KARVONEN M, ARAVANIS C, Blackburn H, BUZINA R . The diet and 15-year death rate in the seven countries study. Am J Epidemiol. 1986; 124(6):903-15. DOI: 10.1093/oxfordjournals.aje.a114480. View

15.

Roe M, Li Q, Bhatt D, Bittner V, Diaz R, Goodman S . Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019; 140(19):1578-1589. PMC: 6830944. DOI: 10.1161/CIRCULATIONAHA.119.042551. View

16.

Ostadal P, Steg P, Poulouin Y, Bhatt D, Bittner V, Chua T . Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2022; 10(5):330-340. DOI: 10.1016/S2213-8587(22)00043-2. View

17.

Holthuis E, Visseren F, Bots M, Peters S . Risk Factor Clusters and Cardiovascular Disease in High-Risk Patients: The UCC-SMART Study. Glob Heart. 2022; 16(1):85. PMC: 8698229. DOI: 10.5334/gh.897. View

18.

Zafeiropoulos S, Farmakis I, Kartas A, Arvanitaki A, Pagiantza A, Boulmpou A . Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial. Atherosclerosis. 2021; 323:37-43. DOI: 10.1016/j.atherosclerosis.2021.03.013. View

19.

Stamler J, Wentworth D, Neaton J . Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256(20):2823-8. View

20.

Hadjiphilippou S, Ray K . Cholesterol-Lowering Agents. Circ Res. 2019; 124(3):354-363. DOI: 10.1161/CIRCRESAHA.118.313245. View